OV329 bets that Phase 1 GABAergic signal translates to seizure reduction in Phase 2 treatment-resistant focal epilepsy patients

Updated 126d ago

Ovid Therapeutics is a clinical-stage biopharmaceutical company developing OV329, a targeted seizure medication for treatment-resistant focal epilepsy that is not yet approved.

OV329 is a GABAergic inhibitor targeting treatment-resistant focal seizures, with expansion into infantile spasms and TSC-associated seizures in pediatric populations. The thesis resolves on whether Phase 2a randomized data demonstrate meaningful seizure frequency reduction over placebo. The primary competitive risk is azetukalner (Xenon/XEN1101), a Kv7 potassium channel opener with late-stage focal epilepsy data, and BHV-7000 from Biohaven, both advancing in the same refractory population.

Status

Intact

Conviction

What could change the thesis?

OV329 Phase 2a in treatment-resistant focal seizures may fail to demonstrate meaningful seizure reduction over placebo, eliminating the lead program's value before any of the earlier-stage expansions (infantile spasms, TSC) can generate data.

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

6 programs · 8 catalysts

Stress Test